Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 23

Sort by

Sort Order Select

Journal Articles

Correlation between real-world (RW) progression-free survival (rwPFS) and overall survival (OS) among patients (Pts) with first-line (1L) chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL) receiving covalent bruton tyrosine kinase inhibitors (cBTKis) or B-cell lymphoma 2 inhibitors (BCL2is)

John M. Burke, Enrico De Nigris, Yunfei Wang, Kathleen Aguilar, John Murphy, Brittani Wayne, Jennifer Prescott, Diana Chirovsky, Inkyu Kim, Siyang Leng, Ira Zackon

Blood (2025) 146 (Supplement 1): 3888.

https://doi.org/10.1182/blood-2025-3888

Published: 2025

Journal Articles

Real-world analysis of treatment patterns and outcomes in older patients with Acute Myeloid Leukemia (AML) in the US community oncology setting

Ira Zackon, Helen Engle, Lisa Herms, Janet Espirito, Zhaohui Su

Blood (2025) 146 (Supplement 1): 5190.

https://doi.org/10.1182/blood-2025-5190

Published: 2025

Journal Articles

Real-world (RW) treatment (Tx) patterns, factors associated with discontinuation and toxicity across covalent BTK inhibitors (cBTKis) in first-line (1L) tx of chronic lymphocytic leukemia (CLL) and small lymphocytic lymphoma (SLL)

John M. Burke, Enrico De Nigris, Yunfei Wang, Kathleen Aguilar, John Murphy, Brittani Wayne, Jennifer Prescott, Diana Chirovsky, Siyang Leng, Ira Zackon

Blood (2025) 146 (Supplement 1): 2111.

https://doi.org/10.1182/blood-2025-2111

Published: 2025

Journal Articles

Real-world hematologic response and treatment patterns among patients with polycythemia vera (PV) treated with ropeginterferon alfa-2b (ropeg)

Malcolm Charles, Zhaohui Su, Kathleen Aguilar, Robert Reid, Ira Zackon, Drew Bernstein, Stefanie Cribb, Edward Jefford, Paul Walden, Kyle Downey

Blood (2025) 146 (Supplement 1): 7342.

https://doi.org/10.1182/blood-2025-7342

Published: 2025

Journal Articles

Real-world utilization of bispecific antibodies for treatment of diffuse large B-cell lymphoma (DLBCL) in the US community oncology setting

Ping Shi, Kathleen Aguilar, Zhaohui Su, Lisa Herms, Junxin Shi, Jessica Paulas, Ira Zackon

Blood (2025) 146 (Supplement 1): 7249.

https://doi.org/10.1182/blood-2025-7249

Published: 2025

Journal Articles

Evolving real-world uptake and patient characteristics of bispecific antibodies in Relapsed/Refractory multiple myeloma: Insights from a US community oncology network

Matthew Whitesell, Zhaohui Su, Lisa Herms, Janet Espirito, Jessica Paulas, Ira Zackon

Blood (2025) 146 (Supplement 1): 5857.

https://doi.org/10.1182/blood-2025-5857

Published: 2025

Journal Articles

Real-world characteristics and outcomes of patients with relapsed/refractory (R/R) diffuse large B cell lymphoma (DLBCL) who received second line therapy, stratified by stem cell transplant status

Helmneh Sineshaw, Helen Latimer, Ira Zackon, Nishitha Reddy, Wan-Yu Tseng, Chuck Wentworth, Juliet Ndukum, Nicole Fulcher, David Andorsky

Blood (2025) 146 (Supplement 1): 8063.

https://doi.org/10.1182/blood-2025-8063

Published: 2025

Journal Articles

Maintaining higher hemoglobin levels is associated with improved overall survival in Myelodysplastic Syndromes (MDS): A real-world retrospective analysis of electronic health records from a US community setting over the past 20 years

Zhaohui Su, Matthew Whitesell, Lisa Herms, Jessica Paulas, Ira Zackon

Blood (2025) 146 (Supplement 1): 2095.

https://doi.org/10.1182/blood-2025-2095

Published: 2025

Journal Articles

Real-World Treatment Patterns and Molecular Response (MR) Among Patients with Newly Diagnosed Chronic-Phase Chronic Myeloid Leukemia (CML-CP) in a Large Community Oncology Setting

Ira Zackon, April Beeks, David Wei, Chuck Wentworth, Jinhong Guo, Courtney McDermott, Kejal Jadhav, Lisa Herms, Andrea Damon, Islam Sadek, Christopher B. Benton

Blood (2024) 144 (Supplement 1): 6611.

https://doi.org/10.1182/blood-2024-210681

Published: 2024

Journal Articles

Treatment with Zanubrutinib in Patients with Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma Who Were Previously Treated with Another Bruton Tyrosine Kinase Inhibitor in a US Community Oncology Setting

David Andorsky, Brittani Wayne, Chuck Wentworth, Yunfei Wang, Scott Goldfarb, Keri Yang, Erlene Kuizon Seymour, Mark Balk, Gregory A. Maglinte, Ira Zackon

Blood (2024) 144 (Supplement 1): 7763.

https://doi.org/10.1182/blood-2024-205940

Published: 2024

Journal Articles

The Evolution of Treatment Patterns for Chronic Lymphocytic Leukemia (CLL): Trends in the US Community Oncology Setting from 2015 to 2024

Zhaohui Su, Lisa Herms, Jessica Paulus, Nicholas Robert, Ira Zackon

Blood (2024) 144 (Supplement 1): 6792.

https://doi.org/10.1182/blood-2024-210905

Published: 2024

Journal Articles

Real-World Utilization of Bispecific Antibodies for Treatment of Relapsed/Refractory Multiple Myeloma in the US Community Oncology Setting

Lisa Herms, Zhaohui Su, Jessica Paulus, Ira Zackon

Blood (2024) 144 (Supplement 1): 2410.

https://doi.org/10.1182/blood-2024-208825

Published: 2024

Journal Articles

Using NLP to Identify CAR T-Cell Therapy Recipients from Oncology Progress Notes

Avi Raju, Lisa Herms, Zhaohui Su, Ira Zackon, Jessica Paulus

Blood (2024) 144 (Supplement 1): 7486.

https://doi.org/10.1182/blood-2024-205446

Published: 2024

Journal Articles

Trends in Real-World Characteristics and Outcomes of Patients with Diffuse Large B-Cell Lymphoma Treated in the US Community Oncology Setting Pre- and Post-CAR-T Approvals

Lisa Herms, Zhaohui Su, Jessica Paulus, Ira Zackon

Blood (2024) 144 (Supplement 1): 3094.

https://doi.org/10.1182/blood-2024-208973

Published: 2024

Journal Articles

Clinical Outcomes and Adverse Events Among Patients with Chronic Lymphocytic Leukemia/ Small Lymphocytic Lymphoma (CLL/SLL) Initiating First-Line (1L) Ibrutinib: Analysis of Subgroups Receiving Subsequent Second Generation (2G) Bruton Tyrosine Kinase Inhibitors, Non-Bruton Tyrosine Kinase Inhibitor Therapy, or Ibrutinib Retreatment in the US Community Oncology Setting

John M. Burke, Ira Zackon, Brittani Wayne, Yunfei Wang, John Murphy, Jennifer Prescott, Shravanthi Gandra, Siyang Leng, Enrico De Nigris

Blood (2024) 144 (Supplement 1): 7811.

https://doi.org/10.1182/blood-2024-203667

Published: 2024

Journal Articles

Real-World Baseline Characteristics and Preliminary Outcomes in Patients with Myelofibrosis Treated with Momelotinib in the US Community Oncology Practice Setting

Luke Fletcher, Nicole Niehoff, Sneha Sura, Tom Liu, Karen Todoroff, William Zhang, Ira Zackon

Blood (2024) 144 (Supplement 1): 2430.

https://doi.org/10.1182/blood-2024-199834

Published: 2024

Journal Articles

Demographics and Mortality of Patients Diagnosed with Multiple Myeloma Treated in the US Community Oncology Setting from 2018 to 2023: Assessing Trends in the Pre-, Peri- and Post-Pandemic Eras

Lisa Herms, Zhaohui Su, Jessica Paulus, Ira Zackon

Blood (2024) 144 (Supplement 1): 6939.

https://doi.org/10.1182/blood-2024-208788

Published: 2024

Journal Articles

Recent Patterns of Care with BTK Inhibitors and Distribution of Social Determinants of Health Among Patients with CLL/SLL in the US Community Setting

David J Andorsky, Ira Zackon, Thomas W Wilson, Kathleen M Aguilar, Chuck Wentworth, Yunfei Wang, Scott Goldfarb, Keri Yang, Erlene Kuizon Seymour, Mark Balk, Gregory A Maglinte

Blood (2023) 142 (Supplement 1): 2413.

https://doi.org/10.1182/blood-2023-172880

Published: 2023

Journal Articles

Treatment Patterns and Overall Survival (OS) Among Patients with Myelodysplastic Syndromes (MDS) Treated in the US Community Oncology Setting: A Real-World Retrospective Observational Study

Roger M. Lyons, Wei-Han Cheng, Laura Moore-Schiltz, Ping Shi, Anders Svensson, Cat N. Bui, Jessica E. Hutti, Ann Marie McNeill, Elizabeth S. Mearns, Archibong Yellow-Duke, Ira Zackon

Blood (2022) 140 (Supplement 1): 6938–6939.

https://doi.org/10.1182/blood-2022-163098

Published: 2022

Journal Articles

Characteristics, Blood Counts, Treatments, and Clinical Outcomes of 5871 Patients with Polycythemia Vera Treated in US Community Practices

Roger M. Lyons, Kathleen M. Aguilar, Lavanya Sudharshan, Divea Venkatasetty, Juliet Ndukum, Ira Zackon, Jingbo Yu

Blood (2022) 140 (Supplement 1): 13310–13311.

https://doi.org/10.1182/blood-2022-163416

Published: 2022

Update search

NARROW

Publications

Format

Article Type

Topics

Date

Availability

Real-world analysis of treatment patterns and outcomes in older patients with Acute Myeloid Leukemia (AML) in the US community oncology setting

Real-world (RW) treatment (Tx) patterns, factors associated with discontinuation and toxicity across covalent BTK inhibitors (cBTKis) in first-line (1L) tx of chronic lymphocytic leukemia (CLL) and small lymphocytic lymphoma (SLL)

Real-world hematologic response and treatment patterns among patients with polycythemia vera (PV) treated with ropeginterferon alfa-2b (ropeg)

Real-world utilization of bispecific antibodies for treatment of diffuse large B-cell lymphoma (DLBCL) in the US community oncology setting

Evolving real-world uptake and patient characteristics of bispecific antibodies in Relapsed/Refractory multiple myeloma: Insights from a US community oncology network

Real-world characteristics and outcomes of patients with relapsed/refractory (R/R) diffuse large B cell lymphoma (DLBCL) who received second line therapy, stratified by stem cell transplant status

Maintaining higher hemoglobin levels is associated with improved overall survival in Myelodysplastic Syndromes (MDS): A real-world retrospective analysis of electronic health records from a US community setting over the past 20 years

Real-World Treatment Patterns and Molecular Response (MR) Among Patients with Newly Diagnosed Chronic-Phase Chronic Myeloid Leukemia (CML-CP) in a Large Community Oncology Setting

Treatment with Zanubrutinib in Patients with Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma Who Were Previously Treated with Another Bruton Tyrosine Kinase Inhibitor in a US Community Oncology Setting

The Evolution of Treatment Patterns for Chronic Lymphocytic Leukemia (CLL): Trends in the US Community Oncology Setting from 2015 to 2024

Real-World Utilization of Bispecific Antibodies for Treatment of Relapsed/Refractory Multiple Myeloma in the US Community Oncology Setting

Using NLP to Identify CAR T-Cell Therapy Recipients from Oncology Progress Notes

Trends in Real-World Characteristics and Outcomes of Patients with Diffuse Large B-Cell Lymphoma Treated in the US Community Oncology Setting Pre- and Post-CAR-T Approvals

Real-World Baseline Characteristics and Preliminary Outcomes in Patients with Myelofibrosis Treated with Momelotinib in the US Community Oncology Practice Setting

Demographics and Mortality of Patients Diagnosed with Multiple Myeloma Treated in the US Community Oncology Setting from 2018 to 2023: Assessing Trends in the Pre-, Peri- and Post-Pandemic Eras

Recent Patterns of Care with BTK Inhibitors and Distribution of Social Determinants of Health Among Patients with CLL/SLL in the US Community Setting

Treatment Patterns and Overall Survival (OS) Among Patients with Myelodysplastic Syndromes (MDS) Treated in the US Community Oncology Setting: A Real-World Retrospective Observational Study

Characteristics, Blood Counts, Treatments, and Clinical Outcomes of 5871 Patients with Polycythemia Vera Treated in US Community Practices

Email alerts

ASH Publications

American Society of Hematology

Update search

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only